144 results on '"Moller, A."'
Search Results
2. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease
3. Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)
4. Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis
5. SAT-088 Safety and Efficacy of the Natriuretic Peptide Ularitide in Refractory Cirrhotic Ascites: Interim Analysis of a Randomized Controlled Trial
6. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease
7. Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)
8. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF)
9. Evaluation of PXL065 – Deuterium-Stabilized (R)-Pioglitazone in NASH Patients: a Phase 2 randomized placebo-controlled trial (DESTINY-1)
10. SAT-370 PRO-C3 determined active fibrogenesis is a predictor of liverrelated outcomes in patients with chronic hepatitis C
11. FRI-027 Fibroblast activity kills-circulating endotrophin (PRO-C6) is prognostic for liver-related events in patients with cirrhosis from chronic hepatitis C
12. WED-331-YI Subclinical myocardial fibrosis is related to disease severity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
13. WED-421 - Growth differentiation factor 15 in plasma and liver is associated with hepatic oxidative stress in non-alcoholic fatty liver disease
14. SAT-481 - Performance of novel collagen turnover biomarkers in relation to FIB-4 to detect advanced fibrosis in NAFLD
15. SAT-451 - Serological biomarkers of extracellular matrix related disease activity are elevated in patients at risk of NASH with significant liver stiffness
16. WED-287 - Associations between patient-reported outcomes, liver inflammation and fibrosis in patients with primary sclerosing cholangitis
17. WED-325 - Atorvastatin reduces inflammation markers TNF-α, CD62L and MMP2 in a randomised trial
18. FRI-434 - Low sphingolipid levels indicate poor survival in patients with alcohol-related liver disease
19. FRI-424 - Binge drinking acutely induces fatty liver with increased liver stiffness which is readily reversed
20. Prolonged Q–Tc interval in mild portal hypertensive cirrhosis
21. Acute non-selective β-adrenergic blockade reduces prolonged frequency-adjusted Q–T interval (QTc) in patients with cirrhosis
22. SAT495 - The composition of the bile acid pool is closely associated with fibrosis in the heart and liver of patients with cirrhosis
23. Cirrhotic cardiomyopathy
24. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease
25. Dynamics of albumin in plasma and ascitic fluid in patients with cirrhosis
26. Serum YKL-40 is increased in patients with hepatic fibrosis
27. The acid-labile subunit of the ternary insulin-like growth factor complex in cirrhosis: relation to liver dysfunction
28. Increased arterial compliance in decompensated cirrhosis
29. Hepatic amino- to urea-N clearance and forearm amino-N exchange during hypoglycemic and euglycemic hyperinsulinemia in normal man
30. Natural history and etiology of liver disease in patients with previous community-acquired acute non-A, non-B hepatitis: A follow-up study of 178 Danish patients consecutively enrolled in The Copenhagen Hepatitis Acuta Programme in the period 1969–1987
31. SAT-287 - The role of bile acids in the development of structural myocardial changes and cardiac dysfunction in patients with cirrhosis
32. SAT-290 - Liver cirrhosis and wound healing: Activation of von Willebrand factor and platelets
33. SAT-286 - Cardiac fibrosis and coronary atherosclerosis in cirrhosis. Indications of cirrhotic cardiomyopathy?
34. SAT-211 - Loss of colonization resistance in cirrhosis facilitates proton pump inhibitor-associated oralization of the colonic microbiome
35. FRI-399 - Effects of direct-acting antiviral treatment of chronic hepatitis C on macrophage activation, liver stiffness, metabolic liver function and portal hypertension in cirrhosis patients
36. THU-250 - Combinations of inflammatory markers, soluble (s)CD163, mannose receptor (sMR) and neutrophil gelatinase associated lipocalin (NGAL), predicts mortality in patients with acute-on-chronic liver failure
37. SAT-470 - A Serological Marker of Collagen Type III Crosslinking Correlates Strongly with Severity of Liver Disease
38. SAT-461 - A Liver Score that Combines Direct Markers of Extracellular Matrix Formation with Platelet Count, INR and Age Accurately Diagnose Liver Fibrosis and Cirrhosis in Patients with Alcohol Overuse
39. SAT-460 - Livertrailcom: A Smartphone App to Predict Presence of Liver Fibrosis in Patients with Alcohol Overuse
40. SAT-043 - Aquaporin-2 in Cirrhosis: Relation to Disease Severity, Markers of Renal Function and Impact on Development of Renal Insufficiency and Mortality
41. FRI-194 - Mortality among Patients with Chronic Hepatitis C and Cirrhosis in Denmark – A Nationwide Danhep Cohort Study
42. FRI-466 - Soluble CD163, a Marker of Macrophage Activation, is Increased in Early Allograft Dysfunction after Liver Transplantation
43. FRI-285 - Adipose Tissue Insulin Resistance is Associated with Macrophage Activation in Non-Diabetic Patients with Non-Alcoholic Fatty Liver Disease
44. FRI-360 - Effects of Transjugular Intrahepatic Portosystemic Shunt (Tips) on Blood Volume Distribution in Patients with Cirrhosis
45. THU-283 - Macrophage Activation Assessed by Soluble CD163 and Soluble Mannose Receptor is Associated with Liver Injury in Patients with Acetaminophen Overdose
46. 591 BACTERIAL DNA MEASUREMENTS IN PATIENTS WITH CIRRHOSIS UNDERGOING TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) INSERTION
47. 225 THE PROTEIN FINGERPRINT TECHNOLOGY REFLECTS LIVER FUNCTION AND DETECTS CLINICALLY SIGNIFICANT PORTAL HYPERTENSION IN PATIENTS WITH ALCOHOLIC LIVER CIRRHOSIS
48. 206 RIFAXIMIN IN THE TREATMENT AND PROPHYLAXIS OF HEPATIC ENCEPHALOPATHY IN CHRONIC LIVER DISEASE: A META-ANALYSIS
49. 710 TIMP-1 IN PATIENTS WITH CIRRHOSIS: RELATION TO LIVER DYSFUNCTION, PORTAL HYPERTENSION, AND HAEMODYNAMIC CHANGES
50. 1342 CHANGE IN SOLUBLE CD163, A MARKER OF ACTIVATED MACROPHAGES, IS ASSOCIATED WITH IMPROVEMENT IN LIVER ENZYMES AND METABOLIC PROFILE IN OBESE CHILDREN DURING LIFESTYLE INTERVENTION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.